Compare Nebius Group NV (NBIS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Recursion Pharmaceuticals Inc — how do they compare? Nebius Group NV trades at $219.15 (market cap $46.37B), while Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B). The key difference: Nebius Group NV is far larger — about 30.3× Recursion Pharmaceuticals Inc's market cap, and Nebius Group NV is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| NBIS | RXRX | |
|---|---|---|
Market Cap | $46.37B | $1.53B |
Sector | Technology | Health |
52-Week High | $286.69 | $6.79 |
52-Week Low | $50.40 | $2.84 |
Enterprise Value | $46.56B | $946.50M |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
